喘可治注射液辅助治疗非小细胞肺癌的临床疗效及对T淋巴细胞亚群的影响

Clinical Effect of Chuankezhi Injection in the Adjuvant Treatment of Non-small Cell Lung Cancer and Its Impact on Tlymphocyte Subsets

目的探究喘可治注射液辅助治疗非小细胞肺癌的临床疗效及对T淋巴细胞亚群的影响。方法选择2010年7月—2014年9月在新疆维吾尔自治区胸科医院接受治疗的102例非小细胞肺癌患者,采用随机数字表法将患者分为对照组和观察组,每组51例。对照组患者采用GP化疗方案(顺铂+吉西他滨)治疗,观察组在对照组治疗基础上联合喘可治注射液辅助治疗。比较两组患者临床疗效及毒副作用,治疗前后T淋巴细胞亚群(CD+3细胞分数、CD+4细胞分数、CD+8细胞分数以及CD+4/CD+8细胞比值)、QLQ-C30量表评分(主要包括社会功能、情绪功能、躯体功能以及整体生活质量4个方面)。结果观察组患者临床疗效优于对照组(u=2.534,P=0.011)。治疗前两组患者CD+3细胞分数、CD+4细胞分数、CD+8细胞分数、CD+4/CD+8细胞比值比较,差异无统计学意义(P>0.05);治疗后观察组患者CD+3细胞分数、CD+4细胞分数、CD+4/CD+8细胞比值均高于对照组(P<0.01)。治疗前两组患者社会功能、情绪功能、躯体功能以及整体生活质量评分比较,差异无统计学意义(P>0.05);治疗后观察组患者社会功能、情绪功能、躯体功能以及整体生活质量评分均高于对照组(P<0.01)。观察组患者白细胞计数(WBC)减少、血小板计数(PLT)减少、血红蛋白(HGB)水平降低及恶心呕吐发生率均低于对照组(P<0.05)。结论喘可治注射液辅助治疗非小细胞肺癌的临床疗效确切,能有效提高患者免疫功能,改善患者生活质量,且毒副作用较少。

Objective To investigate the clinical effect of chuankezhi injection in the adjuvant treatment of non-small cell lung cancer and its impact on T-lymphocyte subsets. Methods A total of 102 patients with non-small cell lung cancer were selected in the Chest Hospital of Xinjiang Uygur Autonomous Region from July 2010 to September 2014,and they were divided into control group and observation group according to random number table, each of 51 cases. Patients of both groups received GP chemotherapy regimens（ cisplatin combined with gemcitabine）,while patients of observation group received extra chuankezhi injection. Clinical effect, incidence of toxic and side effect, T-lymphocyte subsets（ including CD＋3cell percentage,CD＋4cell percentage,CD＋8cell percentage and CD＋4/ CD＋8cell ratio） and QLQ-C30 score（ including social function,emotional function,physical function and global quality of life） before and after treatment were compared between the two groups. Results the clinical effect of observation group was statistically significantly better than that of control group（ u =2. 534,P = 0. 011）. No statistically significant differences of CD＋3cell percentage,CD＋4cell percentage,CD＋8cell percentage or CD＋4/ CD＋8cell ratio was found between the two groups before treatment,while CD＋3cell percentage,CD＋4cell percentage and CD＋4/ CD＋8cell ratio of observation group were statistically significantly higher than those of control group（ P〈0. 01）. No statistically significant differences of social function score,emotional function score,physical function score or global quality of life score was found between the two groups before treatment（ P〈0. 05）,while above index of observation group was statistically significantly higher than that of control group,respectively（ P〈0. 01）. The incidence of decreased WBC,decreased PLT,decreased HGB level,nausea and vomiting of observation group was statistically significantly lower than that of control group,respectively（ P〈0. 05）. Conclusion Chuankezhi injection has certain clinical effect in the adjuvant treatment of non-small cell lung cancer,which can effectively improve the immunologic function and quality of life with less toxic and side effect.